National Cancer Institute Cancer Center designation and 30-day mortality for hospitalized, immunocompromised cancer patients.
OBJECTIVE
To examine 30-day mortality and National Cancer Institute (NCI) designation for cancer patients who are immunocompromised and hospitalized.


METHODS
Secondary analysis of 1998 and 1999 hospital claims, cancer registry, and vital statistics (n = 10,370) linked to survey and administrative data from 160 Pennsylvania hospitals. Logistic regression models estimated the effects of NCI designation on the likelihood of 30-day mortality.


RESULTS
NCI-designated centers were associated with a 33% reduction in the likelihood of death, after adjusting for patient, hospital, and nursing characteristics.


CONCLUSIONS
Immunocompromised cancer patients have lower mortality in NCI-designated hospitals. Identification and adoption of care processes from these institutions may improve mortality.
Friese
Christopher R
CR
University of Michigan School of Nursing, Ann Arbor, USA. cfriese@umich.edu
Silber
Jeffrey H
JH
Aiken
Linda H
LH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002173:Cancer Care Facilities; D003625:Data Collection; D005260:Female; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000150:complications / Q000401:mortality* / Q000473:pathology; D009859:Oncology Nursing; D013727:Terminal Care; D014481:United States